S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
Secure your stake in the Smart Home industry. (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable

Bio-Path Stock Price, News & Analysis (NASDAQ:BPTH)

$0.46
0.00 (0.00%)
(As of 11/28/2023 ET)
Compare
Today's Range
$0.45
$0.47
50-Day Range
$0.36
$0.75
52-Week Range
$0.32
$2.35
Volume
60,128 shs
Average Volume
863,806 shs
Market Capitalization
$5.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Bio-Path MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
5.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.62mentions of Bio-Path in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.67) to ($1.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars


BPTH stock logo

About Bio-Path Stock (NASDAQ:BPTH)

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

BPTH Stock Price History

BPTH Stock News Headlines

Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Bio-Path Holdings Inc
Bio-Path GAAP EPS of -$0.32 beats by $0.02
Bio-Path Hldgs: Q3 Earnings Insights
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Preview: Bio-Path Holdings's Earnings
GRI Bio to sell 4.13M shares for holders
BPTH, HARP and BTDR among mid-day movers
What's Going On With Bio-Path Holdings Stock?
Bio-Path Holdings, Inc.'s (NASDAQ:BPTH) Profit Outlook
Bio-Path Holdings's Earnings Outlook
Why Bio-Path Holdings (BPTH) Stock Is Down 45%
See More Headlines
Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2023
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/29/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPTH
Fax
N/A
Employees
10
Year Founded
2007

Profitability

Net Income
$-13,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.98 per share

Miscellaneous

Free Float
11,992,000
Market Cap
$5.68 million
Optionable
Not Optionable
Beta
1.11

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Peter H. Nielsen MBA (Age 74)
    Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer
    Comp: $722.68k
  • Mr. Douglas P. Morris (Age 67)
    Co-Founder, Director of Investor Relations, Secretary & Director
    Comp: $110.68k
  • Mr. Anthony Price
    Senior Vice President of Finance, Accounting & Administration
  • Dr. Ana Tari Ashizawa Ph.D.
    MBA, Senior Vice President of Research, Development & Clinical Design














BPTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Path stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BPTH shares.
View BPTH analyst ratings
or view top-rated stocks.

How have BPTH shares performed in 2023?

Bio-Path's stock was trading at $1.51 at the beginning of 2023. Since then, BPTH stock has decreased by 69.5% and is now trading at $0.4603.
View the best growth stocks for 2023 here
.

Are investors shorting Bio-Path?

Bio-Path saw a decrease in short interest in November. As of November 15th, there was short interest totaling 695,700 shares, a decrease of 28.2% from the October 31st total of 969,600 shares. Based on an average trading volume of 2,640,000 shares, the days-to-cover ratio is presently 0.3 days.
View Bio-Path's Short Interest
.

When is Bio-Path's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our BPTH earnings forecast
.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.02. During the same quarter last year, the company earned ($0.49) EPS.

When did Bio-Path's stock split?

Bio-Path's stock reverse split on the morning of Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by many different retail and institutional investors. Top institutional investors include Walleye Capital LLC (1.69%).
View institutional ownership trends
.

How do I buy shares of Bio-Path?

Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BPTH) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -